<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Iridex Corporation — News on 6ix</title>
<link>https://6ix.com/company/iridex-corporation</link>
<description>Latest news and press releases for Iridex Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/iridex-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683584ee78dffbe2df0fd4e4.webp</url>
<title>Iridex Corporation</title>
<link>https://6ix.com/company/iridex-corporation</link>
</image>
<item>
<title>Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-new-partnership-with-eyeprogpo-to-expand-member-access-to-retina-laser-technology</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-new-partnership-with-eyeprogpo-to-expand-member-access-to-retina-laser-technology</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based</description>
</item>
<item>
<title>Iridex Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-26-2026</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company’s management team will host a corresponding conferen</description>
</item>
<item>
<title>Iridex Announces Plans to Relocate Headquarters</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-plans-relocate-headquarters-120000672</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-plans-relocate-headquarters-120000672</guid>
<pubDate>Mon, 02 Feb 2026 12:00:00 GMT</pubDate>
<description>Move expected to generate significant cost savingsMOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company’s headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter o</description>
</item>
<item>
<title>Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-preliminary-operational-financial-120000116</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-preliminary-operational-financial-120000116</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>Demonstrating continued revenue growth, operational efficiencies and positive cash flowMOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter</description>
</item>
<item>
<title>Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-publication-independent-study-120000379</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-publication-independent-study-120000379</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effect</description>
</item>
<item>
<title>Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-thermal-dynamics-study-120000300</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-thermal-dynamics-study-120000300</guid>
<pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma.1 Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center</description>
</item>
<item>
<title>Iridex to Present at the Sidoti Year-End Virtual Investor Conference</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-present-sidoti-end-virtual-120000085</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-present-sidoti-end-virtual-120000085</guid>
<pubDate>Fri, 05 Dec 2025 12:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Sidoti Year-End Virtual Investor Conference. Management is scheduled to present on Thursday, December 11 at 10:45 am ET. Interested parties may access a live and archived webcast of the</description>
</item>
<item>
<title>Iridex Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-reports-third-quarter-2025-210500424</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-reports-third-quarter-2025-210500424</guid>
<pubDate>Tue, 11 Nov 2025 21:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in t</description>
</item>
<item>
<title>Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-report-third-quarter-2025-200500130</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-report-third-quarter-2025-200500130</guid>
<pubDate>Tue, 28 Oct 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2025 and provide a business update after the close of trading on Tuesday, November 11, 2025. The Company’s management team will host a corresponding conference c</description>
</item>
<item>
<title>Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-corporation-receives-formal-notification-200500132</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-corporation-receives-formal-notification-200500132</guid>
<pubDate>Tue, 09 Sep 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced that it has received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that Iridex has evidenced compliance with the continued listing requirements. As previously reported, on May 14, 2025, Iridex r</description>
</item>
<item>
<title>Iridex Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-reports-second-quarter-2025-200500591</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-reports-second-quarter-2025-200500591</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Financial Highlights Generated total revenue of $13.6 million, representing growth of 7% year-over-year and 14% sequential growth versus</description>
</item>
<item>
<title>Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-report-second-quarter-2025-200500061</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-report-second-quarter-2025-200500061</guid>
<pubDate>Tue, 29 Jul 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the second quarter 2025 and provide a business update after the close of trading on Tuesday, August 12, 2025. The Company’s management team will host a corresponding c</description>
</item>
<item>
<title>Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-first-patient-enrolled-110000945</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-first-patient-enrolled-110000945</guid>
<pubDate>Tue, 24 Jun 2025 11:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPuls</description>
</item>
<item>
<title>Iridex Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-reports-first-quarter-2025-200500923</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-reports-first-quarter-2025-200500923</guid>
<pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenu</description>
</item>
<item>
<title>Iridex to Report First Quarter 2025 Financial Results on May 13, 2025</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-report-first-quarter-2025-200500324</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-report-first-quarter-2025-200500324</guid>
<pubDate>Wed, 30 Apr 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company’s management team will host a corresponding conf</description>
</item>
<item>
<title>Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-preliminary-operational-financial-200500587</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-preliminary-operational-financial-200500587</guid>
<pubDate>Mon, 14 Apr 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8</description>
</item>
<item>
<title>Iridex to Host Strategic Vision Call on April 16, 2025</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-host-strategic-vision-call-200500231</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-host-strategic-vision-call-200500231</guid>
<pubDate>Wed, 09 Apr 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel’s strategic vision for the Company following Novel’s recent strategic investment in Iridex. The Company’s management team will host</description>
</item>
<item>
<title>Iridex Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-reports-fourth-quarter-full-200500715</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-reports-fourth-quarter-full-200500715</guid>
<pubDate>Thu, 27 Mar 2025 20:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 28, 2024. Fourth Quarter 2024 Results & Recent Highlights Achieved positive adjusted EBITDA in the fourth quarter of 2024Successfully implemented pr</description>
</item>
<item>
<title>Iridex Announces Strategic Investment in the Company</title>
<link>https://6ix.com/company/iridex-corporation/news/iridex-announces-strategic-investment-company-131500596</link>
<guid isPermaLink="true">https://6ix.com/company/iridex-corporation/news/iridex-announces-strategic-investment-company-131500596</guid>
<pubDate>Wed, 19 Mar 2025 13:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the closing of a strategic investment in the company resulting in $10 million of gross proceeds along with an option by the investor to fund up to $10 million of additional proceeds for future growth initiatives (the “Transaction”). The</description>
</item>
</channel>
</rss>